Serialisation — looking for value-added opportunities
Recipharm's Staffan Widengren, Director Corporate Projects, discusses why CMOs should be focusing on the value-added opportunities presented by serialisation.
The European Falsified Medicines Directive (EU FMD) is just months from its enforcement date. Yet, the industry still has a long way to go if compliance is to be achieved.
TraceLink’s Global Drug Supply Safety and Traceability Report, which includes results from a survey of over 600 respondents, found that 88% of CMOs are concerned that equipment shortages will affect their ability, or their customers’ ability, to comply with the regulations. The survey also revealed that 94% of CMOs felt ‘somewhat’ or ‘very prepared’ for serialisation, yet less than half (42%) had not begun preparing.
Staffan Widengren, Director Corporate Projects at Recipharm, discusses the results of the survey and why CMOs should be focusing on the value-added opportunities presented by serialisation.
Do you think CMOs are right to be concerned about potential equipment shortages in the lead up to the EU FMD?
It’s a legitimate concern, vendors are dealing with significant order volumes and having to prioritize larger customers — lead times from machine vendors have increased significantly from order to delivery in the last year. For a standard machine the lead time today is likely to be over 8 months — Recipharm was working to a timescale of less than 6 months when it started its serialisation program. For businesses yet to select a vendor, they will have to opt for standard machines without customization.
78% of CMOs were already working on value-added projects — why do you think CMOs in the EU are so focused on added-value at this stage?
As the investments required of companies working towards serialisation are so high for a compliance requirement, CMOs are looking for areas where they could gain and add value both internally and for their customers. Developing means of interpreting and utilizing the big data being generated to make improvements in efficiency is a top priority for many.
Why do you think CMOs felt prepared for serialisation despite not having begun any actual preparations?
There’s little doubt that CMOs are aware of the requirement and have begun planning in some way. However, as the serialisation challenge is completely new, there has been some naivety from many businesses and many have failed to appreciate the preparation time required, the lengthening lead times for machines and software from vendors, the complexity of onboarding customers and the difficulty involved in securing approval from top management concerning capex and costs.
Staffan Widengren will be presenting at FutureLink Munich, 5-7 June 2018, on the ‘Final countdown: focus areas for a CDMO before February 2019'.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance